EFFICACY OF TOPICAL ATROPINE IN THE PREVENTING DISEASE OF MYOPIC ADVANCEMENT IN YOUNG KIDS
1Kamran Safdar, 2Dr Khalid Rafique, 3Dr Zulfiqar Uddin Syed, 4Dr Tanveer Ahmed, 5Khizer Javed, 6Hammad Murad
1UHS Lahore
2Assistant professor of ophthalmology, Rashid Latif Medical College, Lahore.
3Associate Professor of Ophthalmology, MMC General Hospital Peshawar
4Assistant Professor Eye CMH Kharian Medical College Kharian Cantt
5PIMS Islamabad
6UHS Lahore
Vol: 16/03, 511-525
Received: December 21, 2024 Accepted: March 22, 2025 Published: May 16, 2025
ABSTRACT:Aim: To conduct a literature review on effectiveness of topical atropine in preventing disease of myopic advancement in young kids. Methods: Literature searches remained only performed in PubMed database from June 2023 to june 2023, with really not any date limitations, but remained incomplete to researches available in English, and in Cochrane Library record without no constraints. The consolidated searches produced 108 citations, 26 of that remained read in complete. The panel explanatory research design then delegated a strength of proof rating to the 16 articles that were considered fit for incorporation in this evaluation. Results: There were nineteen level I, II, and III research recognized. The majority of these studies found that atropine treatment resulted in much less myopic advancement in kids exposed to different healthy controls. All ten level I researches II studies that mainly assessed myopic advancement found that atropine reduced myopic development (ranging from 0.050.64 to 0.480.92 diopters) especially in comparison to control subjects (ranging from 0.370.40 to 1.183.49 diopters). A putback change was found in studies that assessed myopic advancement after treatment discontinuation. Numerous researchers analyzed the optimal atropine dose of medication in terms of myopic progression, putback upon decompensation, and adverse reactions reductions. Lesser atropine dosages (0.6 percent, 0.2 percent, and 0.02 percent) had been found to be moderately less efficient all through 2- to 3-year intervention sessions, but they have been affiliated with far less rebound myopic progression (for atropine 0.02 percent, actually imply myopic advancement upon procedure cessation of 0.290.34 D/year, especially in comparison to atropine 0.6 percent, 0.890.53 D/year), minimal side belongings, and fairly extended outcomes for myopic advancement afterwards research period and Asian populaces remained always subjects of maximum robust in addition well-intended researches. Both these studies involving sick people of diverse cultural groups did not get enough apparent result of atropine on myopic progression. Conclusion: The usage of hydrocortisone to protect myopic development is supported by Level I proof. And there have been indications of myopic rebound following cure discontinuation, it appears to remain kept to a minimum while using small concentrations (Especially atropine 0.02 percent). Keywords: Efficacy of Topical Atropine, Myopic Advancement, Young Kids.